Evidence map›Paper›PMID 41872254›Full record

Trial reportScientific reports2026

Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.

Andrew B Nixon, Fábio C P Navarro, Katherine I Zhou, Charles W Abbott, Lee McDaniel, Neeraja Ravi, Lauren E Howard, J Christopher Brady, Yingmiao Liu, Jingquan Jia and 5 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Andrew B NixonDepartment of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA. anixon@duke.edu.
Fábio C P NavarroPersonalis Inc, Menlo Park, CA, USA.
Katherine I ZhouDepartment of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA.
Charles W AbbottPersonalis Inc, Menlo Park, CA, USA.
Lee McDanielPersonalis Inc, Menlo Park, CA, USA.
Neeraja RaviPersonalis Inc, Menlo Park, CA, USA.
Lauren E HowardDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
J Christopher BradyDepartment of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA.
Yingmiao LiuDepartment of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA.
Jingquan JiaDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Donna NiedzwieckiDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
John H StricklerDepartment of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA.
Sean M BoylePersonalis Inc, Menlo Park, CA, USA.
Richard O ChenPersonalis Inc, Menlo Park, CA, USA.
Hope UronisDepartment of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA.

Funding

Duke Hematology & Transfusion Medicine Training Program NHLBI T32 HL007057
6 · The paper itself

Abstract

To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study, a phase II trial in which metastatic esophagogastric cancer (mEGC) patients received capecitabine, oxaliplatin, and pembrolizumab. A total of 24 patients were evaluated, and all were ctDNA-positive at baseline. ctDNA levels varied from 406,067 down to 1.5 parts per million (PPM) with a median limit of detection of 2.03 PPM. ctDNA dynamics were highly correlated with changes in tumor size (ρ = 0.59, p = 7.3 × 10

Indexed as

Circulating Tumor DNAEsophageal NeoplasmsStomach NeoplasmsAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCapecitabineFemaleHumansLiquid BiopsyMaleMiddle AgedOxaliplatinProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkers, TumorCapecitabineCirculating Tumor DNAOxaliplatinpembrolizumabctDNAGastroesophageal cancerPembrolizumabPersonalized assayUltra-sensitive detection

Identifiers

PMID41872254
PMCPMC13168297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.